WO1995005604A3 - Procedes de diagnostic de la maladie d'alzheimer - Google Patents

Procedes de diagnostic de la maladie d'alzheimer Download PDF

Info

Publication number
WO1995005604A3
WO1995005604A3 PCT/US1994/008903 US9408903W WO9505604A3 WO 1995005604 A3 WO1995005604 A3 WO 1995005604A3 US 9408903 W US9408903 W US 9408903W WO 9505604 A3 WO9505604 A3 WO 9505604A3
Authority
WO
WIPO (PCT)
Prior art keywords
alzheimer
diagnosis
disease
methods
proteins
Prior art date
Application number
PCT/US1994/008903
Other languages
English (en)
Other versions
WO1995005604A2 (fr
Inventor
Ginger Johnson
Hossein A Ghanbari
Benjamin Wolozin
Carl R Merril
Original Assignee
Molecular Geriatrics Corp
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Geriatrics Corp, Us Health filed Critical Molecular Geriatrics Corp
Priority to AU75569/94A priority Critical patent/AU7556994A/en
Publication of WO1995005604A2 publication Critical patent/WO1995005604A2/fr
Publication of WO1995005604A3 publication Critical patent/WO1995005604A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Electrochemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un procédé permettant d'établir un diagnostic de la maladie d'Alzheimer. Le procédé fait appel à un ensemble unique de protéines que l'on trouve modifiées en concentration chez les malades souffrant de la maladie d'Alzheimer. L'invention se rapporte également à ces protéines et à leurs anticorps, ainsi qu'à des nécessaires pouvant être utilisés pour les tests de diagnostic.
PCT/US1994/008903 1993-08-13 1994-08-15 Procedes de diagnostic de la maladie d'alzheimer WO1995005604A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU75569/94A AU7556994A (en) 1993-08-13 1994-08-15 Methods for the diagnosis of alzheimer's disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10592293A 1993-08-13 1993-08-13
US08/105,922 1993-08-13

Publications (2)

Publication Number Publication Date
WO1995005604A2 WO1995005604A2 (fr) 1995-02-23
WO1995005604A3 true WO1995005604A3 (fr) 2001-09-13

Family

ID=22308530

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/008903 WO1995005604A2 (fr) 1993-08-13 1994-08-15 Procedes de diagnostic de la maladie d'alzheimer

Country Status (2)

Country Link
AU (1) AU7556994A (fr)
WO (1) WO1995005604A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9297244B2 (en) 2011-08-31 2016-03-29 Self-Suspending Proppant Llc Self-suspending proppants for hydraulic fracturing comprising a coating of hydrogel-forming polymer
US9315721B2 (en) 2011-08-31 2016-04-19 Self-Suspending Proppant Llc Self-suspending proppants for hydraulic fracturing

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE218583T1 (de) 1995-03-14 2002-06-15 Praecis Pharm Inc Verbindungen mit aggregations-modulierenden wirkung auf das amyloid protein
US5854215A (en) * 1995-03-14 1998-12-29 Praecis Pharmaceuticals Incorporated Modulators of β-amyloid peptide aggregation
US5817626A (en) * 1995-03-14 1998-10-06 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation
US6303567B1 (en) 1995-03-14 2001-10-16 Praecis Pharmaceuticals, Inc . Modulators of β-amyloid peptide aggregation comprising D-amino acids
AU697842B2 (en) * 1995-08-16 1998-10-15 Hoechst Marion Roussel, Inc. A method of determining the degree of aggregation of the betaA4 peptide
AU7142796A (en) * 1995-10-02 1997-04-28 Erasmus University Rotterdam Diagnosis method and reagents
US6277826B1 (en) 1996-08-27 2001-08-21 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
US5985242A (en) * 1995-10-27 1999-11-16 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
US5919631A (en) * 1996-07-17 1999-07-06 Hoechst Marion Roussel, Inc. Method of determining the degree of aggregation of the β-A4 peptide
FR2751412B3 (fr) * 1996-07-17 1998-09-25 Valbiofrance Methodes de diagnostic in vitro de maladies neurodegeneratives et trousses pour la mise en oeuvre de ces methodes
US5985581A (en) * 1996-07-25 1999-11-16 The Mclean Hospital Corporation Use of presenilin-1 for diagnosis of alzheimers disease
WO1998040748A1 (fr) * 1997-03-14 1998-09-17 Neuromark Diagnostic de troubles neurologiques
NZ525421A (en) * 1998-12-23 2004-10-29 Univ Sydney Method of treating cancer by determining the presence of the disease condition using an assay to determine the binding pattern of immobilised immunoglobulins
CN1279053C (zh) 1999-03-04 2006-10-11 普雷西斯药品公司 含有D－氨基酸的β－淀粉样肽聚集的调节因子
US9845427B2 (en) 2009-10-20 2017-12-19 Self-Suspending Proppant Llc Proppants for hydraulic fracturing technologies
US9868896B2 (en) 2011-08-31 2018-01-16 Self-Suspending Proppant Llc Self-suspending proppants for hydraulic fracturing
US20140000891A1 (en) 2012-06-21 2014-01-02 Self-Suspending Proppant Llc Self-suspending proppants for hydraulic fracturing
US9932521B2 (en) 2014-03-05 2018-04-03 Self-Suspending Proppant, Llc Calcium ion tolerant self-suspending proppants

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991008309A1 (fr) * 1989-12-05 1991-06-13 New England Medical Center Hospitals, Inc. Methodes de detection de maladies neurodegeneratives
EP0444856A2 (fr) * 1990-02-26 1991-09-04 Albert Einstein College Of Medicine Of Yeshiva University Procédé pour la détection de la maladie d'Alzheimer
WO1992000521A1 (fr) * 1990-06-29 1992-01-09 Case Western Reserve University Procedes de diagnostic et de pronostic bases sur des derives solubles du precurseur de proteine beta amyloide
WO1993025911A1 (fr) * 1992-06-17 1993-12-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Diagnostic de la maladie d'alzheimer et de la schizophrenie
WO1994002851A1 (fr) * 1992-07-28 1994-02-03 University Of Cincinnati Test clinique pour la detection de la maladie d'alzheimer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991008309A1 (fr) * 1989-12-05 1991-06-13 New England Medical Center Hospitals, Inc. Methodes de detection de maladies neurodegeneratives
EP0444856A2 (fr) * 1990-02-26 1991-09-04 Albert Einstein College Of Medicine Of Yeshiva University Procédé pour la détection de la maladie d'Alzheimer
WO1992000521A1 (fr) * 1990-06-29 1992-01-09 Case Western Reserve University Procedes de diagnostic et de pronostic bases sur des derives solubles du precurseur de proteine beta amyloide
WO1993025911A1 (fr) * 1992-06-17 1993-12-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Diagnostic de la maladie d'alzheimer et de la schizophrenie
WO1994002851A1 (fr) * 1992-07-28 1994-02-03 University Of Cincinnati Test clinique pour la detection de la maladie d'alzheimer

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9297244B2 (en) 2011-08-31 2016-03-29 Self-Suspending Proppant Llc Self-suspending proppants for hydraulic fracturing comprising a coating of hydrogel-forming polymer
US9315721B2 (en) 2011-08-31 2016-04-19 Self-Suspending Proppant Llc Self-suspending proppants for hydraulic fracturing

Also Published As

Publication number Publication date
AU7556994A (en) 1995-03-14
WO1995005604A2 (fr) 1995-02-23

Similar Documents

Publication Publication Date Title
WO1995005604A3 (fr) Procedes de diagnostic de la maladie d'alzheimer
EP0378924A3 (fr) Détection de maladies ou dysfonctions neurologiques
AU5292290A (en) Diagnostic method for alzheimer's disease: examination of non-neural tissue
ATE223051T1 (de) Verfahren zur diagnose gutartiger prostataerkrankungen
EP0911390A3 (fr) Protéine kinases comme outils pour le diagnostic et le traitement de la maladie d' Alzheimer
DE3786200D1 (de) Diagnostische verfahren zum nachweis von lymphomen bei menschen.
CA2116348A1 (fr) Vaccin sirs et methode de diagnostic
EP1361229A3 (fr) Utilisation de la Tyrosine Kinase (PYK2) pour la production d'anticorps
IL105216A0 (en) Method and kit for the diagnosis of alzheimer's disease
DE240975T1 (de) Menschliches gamma-interferon-spezifisches rezeptorprotein, antikoerper gegen dieses protein, verfahren zur herstellung dieses proteins und dieses antikoerpers und dieses protein und diesen antikoerper enthaltende zusammensetzungen.
ATA328286A (de) Zell-linien und verfahren zur herstellung von humanen monoklonalen antikörpern sowie kit und verfahren zur bestimmung der anwesenheit von p.aeruginosa
DK0433088T3 (da) Monoklonale antistoffer, der reagerer med et humant atheromaassocieret antigen
DE69510336T2 (de) Verfahren zur diagnose von praeklampsie
AU5153398A (en) Diagnostic method for the detection of alzheimer's disease in living patients
DE68921374D1 (de) Monoklonaler Antikörper gegen menschliche Mangan-Superoxiddismutase, Verfahren zu dessen Herstellung, Testreagens, Kit und Testmethode unter Verwendung desselben, Verfahren zur Diagnose von menschlichem Eierstockkrebs und von Herzinfarkt.
DE3879085D1 (de) Snrnp-a-antigen und fragmente davon.
AU2579995A (en) Alpha b crystallin for use in diagnosis and therapy of auto-immune diseases in particular multiple sclerosis
ATE103989T1 (de) Monoklonale antikoerper gegen e7-protein des humanen papillomvirus typ 16, verfahren zu ihrer herstellung sowie ihre verwendung.
ATE93629T1 (de) Verfahren zur diagnose in vitro von menschlichen cytomegalovirusinfektionen und anwendung von monoklonalen antikoerpern gegen cytomegaloviren, die mit einer cytomegalovirusinduzierten proteinkinase reagieren.
AU5157493A (en) Protein specific for alzheimer's disease and method of diagnosing alzheimer's disease through detection of the protein
CA2301716A1 (fr) Trousse de diagnostic pour tests cutanes, et methode applicable
FR2766927B1 (fr) Methodes et kits pour le diagnostic de la maladie d'alzheimer
AU4781193A (en) Clinical test for detection of alzheimer's disease
DE69023500D1 (de) Verfahren zum nachweis von antikörpern gegen streptokinase.
AU7692987A (en) Reagent kit, its use and diagnostic process for the detection of hpasp(human pancreatic specific protein)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: A3

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE MW SD AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG